Drug Profile
AD 6626
Alternative Names: AD-6626Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Stanford University
- Developer ALDEA Pharmaceuticals; Stanford University
- Class Antianaemics; Small molecules
- Mechanism of Action Aldehyde dehydrogenase 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alcoholism; Fanconi's anaemia
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Alcoholism in USA (IV)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Fanconi's-anaemia in USA (PO)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Alcoholism in Australia (IV)